TipRanks
Go Ultimate55% OFF

Korro Bio (KRRO) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Krro-121Urea Cycle Disorders, Ornithine Transcarbamylase (Otc) Deficiency, Urea Cycle Disorders, Inborn, Arginase 1 Deficiency, Nags Deficiency, Carbamylphosphate Synthetase I, Ornithine Transporter Mitochondrial 1, Argininosuccinate Synthase, Argininosuccinate Lyase Deficiency, N-Acetyl Glutamate - Synthetase, Citrin Deficiencyphase1AndPhase2Not Yet RecruitingPhase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCDAug 14, 2026―
Krro-110Aatd, Alpha-1 Anti-Trypsin Deficiencyphase1AndPhase2Active Not RecruitingA Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110Nov 04, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Korro Bio, Inc. (KRRO) have in its pipeline
Korro Bio KRRO is currently developing the following drugs: Krro-121, Krro-110. These drug candidates are in various stages of clinical development as the company works toward FDA approval.